JP2010533206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010533206A5 JP2010533206A5 JP2010516297A JP2010516297A JP2010533206A5 JP 2010533206 A5 JP2010533206 A5 JP 2010533206A5 JP 2010516297 A JP2010516297 A JP 2010516297A JP 2010516297 A JP2010516297 A JP 2010516297A JP 2010533206 A5 JP2010533206 A5 JP 2010533206A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition
- compound
- cell
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 15
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 7
- -1 salt compound Chemical class 0.000 claims 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 229960004679 doxorubicin Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000000771 oncological effect Effects 0.000 claims 4
- 229960003087 tioguanine Drugs 0.000 claims 4
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical group 0.000 claims 3
- 210000005260 human cell Anatomy 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 2
- 108010006654 Bleomycin Proteins 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 2
- 239000012625 DNA intercalator Substances 0.000 claims 2
- 108010092160 Dactinomycin Proteins 0.000 claims 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 claims 2
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 claims 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 claims 2
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 claims 2
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 2
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims 2
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 2
- 101150045355 akt1 gene Proteins 0.000 claims 2
- 229960000548 alemtuzumab Drugs 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940046836 anti-estrogen Drugs 0.000 claims 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims 2
- 230000000340 anti-metabolite Effects 0.000 claims 2
- 229940100197 antimetabolite Drugs 0.000 claims 2
- 239000002256 antimetabolite Substances 0.000 claims 2
- 210000000436 anus Anatomy 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 210000000013 bile duct Anatomy 0.000 claims 2
- 229960001561 bleomycin Drugs 0.000 claims 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 229960002092 busulfan Drugs 0.000 claims 2
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 claims 2
- 229960004117 capecitabine Drugs 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229960005243 carmustine Drugs 0.000 claims 2
- 230000024245 cell differentiation Effects 0.000 claims 2
- 230000012292 cell migration Effects 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960002436 cladribine Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229960000684 cytarabine Drugs 0.000 claims 2
- 229960003901 dacarbazine Drugs 0.000 claims 2
- 229960000640 dactinomycin Drugs 0.000 claims 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 2
- 229960000975 daunorubicin Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960001904 epirubicin Drugs 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 239000000328 estrogen antagonist Substances 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 210000001508 eye Anatomy 0.000 claims 2
- 229960000390 fludarabine Drugs 0.000 claims 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 210000000232 gallbladder Anatomy 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 229940022353 herceptin Drugs 0.000 claims 2
- 229960000908 idarubicin Drugs 0.000 claims 2
- 229960001101 ifosfamide Drugs 0.000 claims 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 229940036646 iodine-131-tositumomab Drugs 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000002429 large intestine Anatomy 0.000 claims 2
- 210000000867 larynx Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 2
- 229960001924 melphalan Drugs 0.000 claims 2
- 230000000394 mitotic effect Effects 0.000 claims 2
- 210000000214 mouth Anatomy 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 230000000955 neuroendocrine Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 210000003899 penis Anatomy 0.000 claims 2
- 229960002340 pentostatin Drugs 0.000 claims 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims 2
- 229960000624 procarbazine Drugs 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 229960004432 raltitrexed Drugs 0.000 claims 2
- 210000000664 rectum Anatomy 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000000278 spinal cord Anatomy 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 229960001052 streptozocin Drugs 0.000 claims 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 229960001196 thiotepa Drugs 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- 229960000303 topotecan Drugs 0.000 claims 2
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 229960003181 treosulfan Drugs 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 210000004291 uterus Anatomy 0.000 claims 2
- 210000001215 vagina Anatomy 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- 229960004528 vincristine Drugs 0.000 claims 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
- 229960004355 vindesine Drugs 0.000 claims 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- 210000003905 vulva Anatomy 0.000 claims 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94936507P | 2007-07-12 | 2007-07-12 | |
| US60/949,365 | 2007-07-12 | ||
| PCT/US2008/069974 WO2009009793A2 (en) | 2007-07-12 | 2008-07-14 | Inhibitors of akt/pkb with anti-tumor activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010533206A JP2010533206A (ja) | 2010-10-21 |
| JP2010533206A5 true JP2010533206A5 (enExample) | 2011-09-01 |
| JP5568471B2 JP5568471B2 (ja) | 2014-08-06 |
Family
ID=40229514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010516297A Expired - Fee Related JP5568471B2 (ja) | 2007-07-12 | 2008-07-14 | 抗腫瘍活性を有するａｋｔ／ｐｋｂの阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8183249B2 (enExample) |
| EP (1) | EP2173352B1 (enExample) |
| JP (1) | JP5568471B2 (enExample) |
| KR (1) | KR101618037B1 (enExample) |
| CN (1) | CN101743007B (enExample) |
| AU (1) | AU2008274956B2 (enExample) |
| BR (1) | BRPI0815563A2 (enExample) |
| CA (1) | CA2695330C (enExample) |
| MX (1) | MX2010000474A (enExample) |
| WO (1) | WO2009009793A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20110834T1 (hr) * | 2004-09-03 | 2011-12-31 | Merck Serono Sa | Piridin metilen azolidinoni i njihova uporaba kao inhibitora fosfoinozitida |
| WO2009009793A2 (en) * | 2007-07-12 | 2009-01-15 | University Of South Florida | Inhibitors of akt/pkb with anti-tumor activity |
| JP5856843B2 (ja) | 2008-05-27 | 2016-02-10 | アンピオ ファーマシューティカルズ，インコーポレイテッド | ジケトピペラジンを用いた医薬組成物 |
| CA2810844C (en) | 2010-09-07 | 2017-03-21 | Dmi Acquisition Corp. | Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions |
| WO2012158197A2 (en) * | 2010-11-11 | 2012-11-22 | Lyndor Biosciences L.L.C. | Compounds useful as akt/pkb modulators and uses thereof |
| WO2012135759A1 (en) | 2011-04-01 | 2012-10-04 | Genentech, Inc. | Combinations of akt inhibitor compounds and abiraterone, and methods of use |
| KR102016182B1 (ko) * | 2011-04-01 | 2019-08-29 | 제넨테크, 인크. | 암 치료에 대한 감수성을 예측하기 위한 바이오마커 |
| CN102225067B (zh) * | 2011-04-29 | 2012-10-03 | 济南环肽医药科技有限公司 | 一种治疗胃癌的药物组合物 |
| MX2014003856A (es) | 2011-10-10 | 2015-01-16 | Ampio Pharmaceuticals Inc | Dispositivos medicos implantables con tolerancia inmune incrementada y metodos para hacerlos e implantarlos. |
| EP2766029B1 (en) | 2011-10-10 | 2020-03-25 | Ampio Pharmaceuticals, Inc. | Treatment of degenerative joint disease |
| SG11201400283RA (en) | 2011-10-28 | 2014-03-28 | Ampio Pharmaceuticals Inc | Treatment of rhinitis |
| GB201207722D0 (en) * | 2012-05-02 | 2012-06-13 | Bergenbio As | Method |
| KR101461626B1 (ko) * | 2012-08-02 | 2014-11-28 | 서울대학교산학협력단 | Ａｋｔ１ 억제제 및 소수성 항암제를 포함하는 항암용 약학적 조성물 |
| WO2014074883A1 (en) * | 2012-11-08 | 2014-05-15 | Lyndor Biosciences L.L.C. | Novel synthesis of ld101 |
| AU2014232728B2 (en) | 2013-03-15 | 2019-02-21 | Ampio Pharmaceuticals, Inc. | Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same |
| KR20160104612A (ko) | 2013-07-26 | 2016-09-05 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조성물 |
| US9986375B2 (en) * | 2014-02-12 | 2018-05-29 | Google Llc | Energy-efficient location determination |
| EP3183240A4 (en) | 2014-08-18 | 2018-06-27 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
| FR3033499A1 (fr) * | 2015-03-11 | 2016-09-16 | Centre Leon-Berard | Composition pour le traitement des tumeurs neuroendocrines pancreatiques |
| US11389512B2 (en) | 2015-06-22 | 2022-07-19 | Ampio Pharmaceuticals, Inc. | Use of low molecular weight fractions of human serum albumin in treating diseases |
| CN116650645A (zh) * | 2020-12-04 | 2023-08-29 | 周清华 | Akt/stat3作为免疫检查点抑制剂的靶点的用途 |
| WO2023168291A1 (en) * | 2022-03-02 | 2023-09-07 | Terremoto Biosciences, Inc. | Covalent modifiers of akt1 and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559157A (en) | 1983-04-21 | 1985-12-17 | Creative Products Resource Associates, Ltd. | Cosmetic applicator useful for skin moisturizing |
| LU84979A1 (fr) | 1983-08-30 | 1985-04-24 | Oreal | Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux |
| US4820508A (en) | 1987-06-23 | 1989-04-11 | Neutrogena Corporation | Skin protective composition |
| US4992478A (en) | 1988-04-04 | 1991-02-12 | Warner-Lambert Company | Antiinflammatory skin moisturizing composition and method of preparing same |
| US5167649A (en) | 1988-08-22 | 1992-12-01 | Zook Gerald P | Drug delivery system for the removal of dermal lesions |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| JP4407008B2 (ja) * | 2000-05-11 | 2010-02-03 | パナソニック株式会社 | カラー画像形成装置 |
| UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| CA2484921A1 (en) | 2002-05-06 | 2003-11-13 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
| LT2574341T (lt) * | 2004-03-29 | 2017-09-11 | University Of South Florida | Navikų ir vėžio efektyvus gydymas triciribino fosfatu |
| US8828451B2 (en) * | 2006-10-04 | 2014-09-09 | University Of South Florida | Akt sensitization of cancer cells |
| WO2009009793A2 (en) | 2007-07-12 | 2009-01-15 | University Of South Florida | Inhibitors of akt/pkb with anti-tumor activity |
-
2008
- 2008-07-14 WO PCT/US2008/069974 patent/WO2009009793A2/en not_active Ceased
- 2008-07-14 CA CA2695330A patent/CA2695330C/en not_active Expired - Fee Related
- 2008-07-14 JP JP2010516297A patent/JP5568471B2/ja not_active Expired - Fee Related
- 2008-07-14 CN CN200880024470.4A patent/CN101743007B/zh not_active Expired - Fee Related
- 2008-07-14 KR KR1020107002898A patent/KR101618037B1/ko not_active Expired - Fee Related
- 2008-07-14 AU AU2008274956A patent/AU2008274956B2/en not_active Ceased
- 2008-07-14 BR BRPI0815563-1A2A patent/BRPI0815563A2/pt not_active IP Right Cessation
- 2008-07-14 MX MX2010000474A patent/MX2010000474A/es active IP Right Grant
- 2008-07-14 US US12/172,831 patent/US8183249B2/en not_active Expired - Fee Related
- 2008-07-14 EP EP08772544.6A patent/EP2173352B1/en active Active
-
2012
- 2012-05-21 US US13/476,098 patent/US9359347B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010533206A5 (enExample) | ||
| JP6724055B2 (ja) | 抗腫瘍アルカロイドを用いる、組み合わせの治療法 | |
| JP2020510032A5 (enExample) | ||
| ES2893155T3 (es) | Composición farmacéutica para inhibir el crecimiento de células madre de cáncer, que contiene un inhibidor de aldehído y un compuesto a base de biguanida | |
| JP2014512356A5 (enExample) | ||
| CN1429114A (zh) | 联合化学疗法 | |
| JP2014512355A5 (enExample) | ||
| JP2008505139A (ja) | 悪心および嘔吐の処置における置換２−チオ−３，５−ジシアノ−４−フェニル−６−アミノピリジン類の使用 | |
| CN101107001A (zh) | 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂 | |
| TW202435896A (zh) | 包含阿茲夫定和化療試劑的抗腫瘤藥物組合物 | |
| KR20100054210A (ko) | 암 치료를 위한 육산화사비소의 병용요법 | |
| JP2017509672A5 (enExample) | ||
| JP2025163103A (ja) | 放射線および／または抗がん治療補助療法としてアデノシン二リン酸リボースの活用 | |
| JP2011514356A5 (enExample) | ||
| WO2024249839A1 (en) | Methods of treating cancer in subjects with prior immune checkpoint inhibitor exposure | |
| WO2019107341A1 (ja) | オゾンナノバブルの抗がん剤 | |
| CN105392478A (zh) | 癌症化学疗法时的副作用降低剂 | |
| RU2482855C2 (ru) | Противоопухолевое средство, включающее производное цитидина и карбоплатин | |
| JP2011502985A5 (enExample) | ||
| US20180015056A1 (en) | Pharmaceutical composition for inhibiting growth of cancer stem cells, containing aldehyde inhibitor and biguanide-based compound | |
| TW202317128A (zh) | 治療化療相關的胃腸道副作用的化合物和方法 | |
| CN116139161A (zh) | Hdac抑制剂联合抗代谢物在抗乳腺癌中的用途 | |
| JP2023040314A (ja) | ウラシル誘導体化合物を含有する抗腫瘍効果増強剤 | |
| WO2013148919A1 (en) | Treatment of multiple myeloma |